Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...

The firm expressed confidence that DexCom has largely overcome its G7-related problems, supporting its maintained Buy rating and price target for the diabetes technology company. In other recent news, ...

Investing.com - Oppenheimer downgraded DexCom (NASDAQ:DXCM) stock rating from Outperform to Perform on Monday, citing multiple challenges facing the continuous glucose monitoring device maker.

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

アメリカ発データ活用のプロフェッショナル、ガーミンジャパン株式会社(以下 Garmin)は、Dexcomのアプリと連携して、Garminデバイスでのグルコース値データの表示を可能にしました。外部アプリやウォッチフェイス、データ項目などをGarminデバイスに ...

The US Food and Drug Administration (FDA) has issued its highest-level recall on more than two million Dexcom Continuous Glucose Monitoring (CGM) devices, warning diabetic patients and healthcare ...

DexCom was hit with a recall and several lawsuits after some customers complained about its devices. Despite this current challenge, the medical device leader is delivering solid financial results.